RESUMEN
Quantitative immunoassays, such as the traditional enzyme-linked immunosorbent assay (ELISA), are used to determine concentrations of an antigen in a matrix of unknown antigen concentration. Magnetic immunoassays, such as the Luminex xMAP technology, allow for the simultaneous detection of multiple analytes and offer heightened sensitivity, specificity, low sample volume requirements, and high-throughput capabilities. Here, we describe a quantitative immunoassay using the Luminex MAGPIX® System to determine the antigen concentration from liquid samples with unknown concentrations. In detail, we describe a newly developed assay for determining production yields of Drosophila S2-produced Marburg virus (MARV) glycoprotein in insect-cell-culture-derived supernatant. The potential applications of this assay could extend to the quantification of viral antigens in fluids derived from both in vitro and in vivo models infected with live MARV, thereby providing additional applications for virological research.
Asunto(s)
Antígenos Virales , Microesferas , Animales , Inmunoensayo/métodos , Antígenos Virales/inmunología , Antígenos Virales/análisis , Marburgvirus/inmunología , Marburgvirus/aislamiento & purificación , Drosophila , Técnicas de Cultivo de Célula/métodos , Línea Celular , Ensayo de Inmunoadsorción Enzimática/métodosRESUMEN
Marburg virus disease (MVD) is a dreadful but exceptional disease. Formerly mainly identified in Uganda, Angola and the Democratic Republic of Congo, it has recently appeared in the Republic of Guinea, Ghana, Equatorial Guinea and Tanzania, adding West Africa to the affected regions. Humans become infected through exposure to bats Roussettus aegyptiacus or during unprotected care of infected people. Five cases are linked to travellers, the last one dates to 2008 and involved a visit to caves colonized by bats. At present, there is no specific treatment or vaccine. Despite its rarity, adventurous travelers should be aware of the risks of exposure and avoid entering places inhabited by bats.
La maladie à virus Marburg est une maladie redoutable mais exceptionnelle. Autrefois identifiée en Ouganda, Angola et République démocratique du Congo, elle a récemment fait son apparition en République de Guinée, au Ghana, en Guinée équatoriale et en Tanzanie, ajoutant l'Afrique de l'Ouest aux régions touchées. Les humains s'infectent lors d'une exposition avec les chauves-souris roussettes d'Égypte ou lors de la prise en charge sans protection de personnes infectées. Cinq cas sont liés à des voyageurs, le dernier remonte à 2008 et était associé à la visite de grottes colonisées par des roussettes d'Égypte. Actuellement, il n'existe aucun traitement spécifique ni vaccin. Malgré sa rareté, les voyageurs aventureux doivent être informés des risques d'exposition et éviter de pénétrer dans des lieux habités par des chauves-souris.
Asunto(s)
Marburgvirus , Viaje , Femenino , Humanos , Masculino , Enfermedad del Virus de Marburg/epidemiología , Enfermedad del Virus de Marburg/transmisión , Enfermedad del Virus de Marburg/virología , Marburgvirus/aislamiento & purificación , Zoonosis Virales/epidemiología , Zoonosis Virales/transmisión , Zoonosis Virales/virología , Quirópteros/virologíaRESUMEN
Marburg virus (MARV), the causative agent of Marburg virus disease, emerges sporadically in sub-Saharan Africa and is often fatal in humas. The natural reservoir for this zoonotic virus is the frugivorous Egyptian rousette bat (Rousettus aegyptiacus) that when infected, sheds virus in the highest amounts in oral secretions and urine. Being fruit bats, these animals forage nightly for ripened fruit throughout the year, including those types often preferred by humans. During feeding, they continually discard partially eaten fruit on the ground that could then be consumed by other Marburg virus susceptible animals or humans. In this study, using qRT-PCR and virus isolation, we tested fruit discarded by Egyptian rousette bats experimentally infected with a natural bat isolate of Marburg virus. We then separately tested viral persistence on fruit varieties commonly cultivated in sub-Saharan Africa using a recombinant Marburg virus expressing the fluorescent ZsGreen1. Marburg virus RNA was repeatedly detected on fruit in the food bowls of the infected bats and viable MARV was recovered from inoculated fruit for up to 6 h.
Asunto(s)
Quirópteros/virología , Frutas/virología , Marburgvirus/aislamiento & purificación , Enfermedades de los Primates/virología , Zoonosis Virales/virología , África del Sur del Sahara , Animales , Quirópteros/fisiología , Quirópteros/orina , Reservorios de Enfermedades/virología , Humanos , Marburgvirus/clasificación , Marburgvirus/genética , Enfermedades de los Primates/transmisión , Primates , Zoonosis Virales/transmisiónRESUMEN
This study aimed to determine the vector competence of bat-associated nycteribiid flies (Eucamsipoda africana) for Marburg virus (MARV) in the Egyptian Rousette Bat (ERB), Rousettus aegyptiacus. In flies fed on subcutaneously infected ERBs and tested from 3 to 43 days post infection (dpi), MARV was detected only in those that took blood during the peak of viremia, 5-7 dpi. Seroconversion did not occur in control bats in contact with MARV-infected bats infested with bat flies up to 43 days post exposure. In flies inoculated intra-coelomically with MARV and tested on days 0-29 post inoculation, only those assayed on day 0 and day 7 after inoculation were positive by q-RT-PCR, but the virus concentration was consistent with that of the inoculum. Bats remained MARV-seronegative up to 38 days after infestation and exposure to inoculated flies. The first filial generation pupae and flies collected at different times during the experiments were all negative by q-RT-PCR. Of 1693 nycteribiid flies collected from a wild ERB colony in Mahune Cave, South Africa where the enzootic transmission of MARV occurs, only one (0.06%) tested positive for the presence of MARV RNA. Our findings seem to demonstrate that bat flies do not play a significant role in the transmission and enzootic maintenance of MARV. However, ERBs eat nycteribiid flies; thus, the mechanical transmission of the virus through the exposure of damaged mucous membranes and/or skin to flies engorged with contaminated blood cannot be ruled out.
Asunto(s)
Quirópteros/virología , Dípteros/virología , Vectores de Enfermedades , Marburgvirus/aislamiento & purificación , Animales , Cuevas , Dípteros/fisiología , Infestaciones Ectoparasitarias/veterinaria , SudáfricaRESUMEN
We report on a supramolecular sensor array using fluorogenic peptide probes and graphene oxide that can target glycoproteins on a viral caspid, facilitating the differentiation of ebola virus from marburg virus and receptor-extensive vesicular stomatitis virus using principal component analysis.
Asunto(s)
Técnicas Biosensibles , Proteínas de la Cápside/química , Ebolavirus/aislamiento & purificación , Colorantes Fluorescentes/química , Glicoproteínas/química , Grafito/química , Péptidos/química , Marburgvirus/aislamiento & purificación , Vesiculovirus/aislamiento & purificaciónRESUMEN
Marburg virus (MARV) causes sporadic outbreaks of severe Marburg virus disease (MVD). Most MVD outbreaks originated in East Africa and field studies in East Africa, South Africa, Zambia, and Gabon identified the Egyptian rousette bat (ERB; Rousettus aegyptiacus) as a natural reservoir. However, the largest recorded MVD outbreak with the highest case-fatality ratio happened in 2005 in Angola, where direct spillover from bats was not shown. Here, collaborative studies by the Centers for Disease Control and Prevention, Njala University, University of California, Davis USAID-PREDICT, and the University of Makeni identify MARV circulating in ERBs in Sierra Leone. PCR, antibody and virus isolation data from 1755 bats of 42 species shows active MARV infection in approximately 2.5% of ERBs. Phylogenetic analysis identifies MARVs that are similar to the Angola strain. These results provide evidence of MARV circulation in West Africa and demonstrate the value of pathogen surveillance to identify previously undetected threats.
Asunto(s)
Quirópteros/virología , Marburgvirus/aislamiento & purificación , África Occidental , Animales , Cuevas , Genoma Viral , Geografía , Funciones de Verosimilitud , Enfermedad del Virus de Marburg/virología , Marburgvirus/clasificación , Marburgvirus/genética , Filogenia , Análisis de Secuencia de ADN , Proteínas Virales/metabolismoRESUMEN
Following the Ebola outbreak in Western Africa in 2013-16, a global effort has taken place for preparedness for future outbreaks. As part of this response, the development of vaccines, treatments and diagnostic tools has been accelerated, especially towards pathogens listed as likely to cause an epidemic and for which there are no current treatments. Several of the priority pathogens identified by the World Health Organisation are haemorrhagic fever viruses. This review provides information on the role of reference materials as an enabling tool for the development and evaluation of assays, and ultimately vaccines and treatments. The types of standards available are described, along with how they can be applied for assay harmonisation through calibration as a relative potency to a common arbitrary unitage system (WHO International Unit). This assures that assay metrology is accurate and robust. We describe reference materials that have been or are being developed for haemorrhagic fever viruses and consider the issues surrounding their production, particularly that of biosafety where the viruses require specialised containment facilities. Finally, we advocate the use of reference materials at early stages, including research and development, as this helps produce reliable assays and can smooth the path to regulatory approval.
Asunto(s)
Técnicas y Procedimientos Diagnósticos , Fiebre Hemorrágica Ebola , Servicios de Información , Infecciones por Virus ARN , Vacunas/normas , África Occidental/epidemiología , Animales , Antígenos Virales/sangre , Virus del Dengue/inmunología , Virus del Dengue/aislamiento & purificación , Virus del Dengue/patogenicidad , Brotes de Enfermedades/prevención & control , Ebolavirus/inmunología , Ebolavirus/aislamiento & purificación , Ebolavirus/patogenicidad , Epidemias/prevención & control , Virus de la Fiebre Hemorrágica de Crimea-Congo/inmunología , Virus de la Fiebre Hemorrágica de Crimea-Congo/aislamiento & purificación , Virus de la Fiebre Hemorrágica de Crimea-Congo/patogenicidad , Fiebre Hemorrágica de Crimea/diagnóstico , Fiebre Hemorrágica de Crimea/inmunología , Fiebre Hemorrágica de Crimea/prevención & control , Fiebre Hemorrágica Ebola/diagnóstico , Fiebre Hemorrágica Ebola/inmunología , Fiebre Hemorrágica Ebola/prevención & control , Humanos , Fiebre de Lassa/diagnóstico , Fiebre de Lassa/inmunología , Fiebre de Lassa/prevención & control , Virus Lassa/inmunología , Virus Lassa/aislamiento & purificación , Virus Lassa/patogenicidad , Enfermedad del Virus de Marburg/diagnóstico , Enfermedad del Virus de Marburg/inmunología , Enfermedad del Virus de Marburg/prevención & control , Marburgvirus/inmunología , Marburgvirus/aislamiento & purificación , Marburgvirus/patogenicidad , Infecciones por Virus ARN/diagnóstico , Infecciones por Virus ARN/inmunología , Infecciones por Virus ARN/prevención & control , Virus ARN/inmunología , Virus ARN/aislamiento & purificación , Virus ARN/patogenicidad , ARN Viral/aislamiento & purificación , Fiebre del Valle del Rift/diagnóstico , Fiebre del Valle del Rift/inmunología , Fiebre del Valle del Rift/prevención & control , Virus de la Fiebre del Valle del Rift/inmunología , Virus de la Fiebre del Valle del Rift/aislamiento & purificación , Virus de la Fiebre del Valle del Rift/patogenicidad , Dengue Grave/diagnóstico , Dengue Grave/inmunología , Dengue Grave/prevención & control , Organización Mundial de la SaludRESUMEN
We detected Marburg virus genome in Egyptian fruit bats (Rousettus aegyptiacus) captured in Zambia in September 2018. The virus was closely related phylogenetically to the viruses that previously caused Marburg outbreaks in the Democratic Republic of the Congo. This finding demonstrates that Zambia is at risk for Marburg virus disease.
Asunto(s)
Quirópteros/virología , Enfermedad del Virus de Marburg/virología , Marburgvirus , Animales , Genes Virales , Humanos , Enfermedad del Virus de Marburg/diagnóstico , Enfermedad del Virus de Marburg/epidemiología , Marburgvirus/clasificación , Marburgvirus/genética , Marburgvirus/aislamiento & purificación , Filogenia , Prevalencia , Vigilancia en Salud Pública , ARN Viral , Zambia/epidemiologíaRESUMEN
INTRODUCTION: In October 2017, a blood sample from a resident of Kween District, Eastern Uganda, tested positive for Marburg virus. Within 24 hour of confirmation, a rapid outbreak response was initiated. Here, we present results of epidemiological and laboratory investigations. METHODS: A district task force was activated consisting of specialised teams to conduct case finding, case management and isolation, contact listing and follow up, sample collection and testing, and community engagement. An ecological investigation was also carried out to identify the potential source of infection. Virus isolation and Next Generation sequencing were performed to identify the strain of Marburg virus. RESULTS: Seventy individuals (34 MVD suspected cases and 36 close contacts of confirmed cases) were epidemiologically investigated, with blood samples tested for MVD. Only four cases met the MVD case definition; one was categorized as a probable case while the other three were confirmed cases. A total of 299 contacts were identified; during follow- up, two were confirmed as MVD. Of the four confirmed and probable MVD cases, three died, yielding a case fatality rate of 75%. All four cases belonged to a single family and 50% (2/4) of the MVD cases were female. All confirmed cases had clinical symptoms of fever, vomiting, abdominal pain and bleeding from body orifices. Viral sequences indicated that the Marburg virus strain responsible for this outbreak was closely related to virus strains previously shown to be circulating in Uganda. CONCLUSION: This outbreak of MVD occurred as a family cluster with no additional transmission outside of the four related cases. Rapid case detection, prompt laboratory testing at the Uganda National VHF Reference Laboratory and presence of pre-trained, well-prepared national and district rapid response teams facilitated the containment and control of this outbreak within one month, preventing nationwide and global transmission of the disease.
Asunto(s)
Técnicas de Laboratorio Clínico/métodos , Control de Enfermedades Transmisibles/métodos , Brotes de Enfermedades , Enfermedad del Virus de Marburg/epidemiología , Enfermedad del Virus de Marburg/patología , Marburgvirus/aislamiento & purificación , Adulto , Animales , Análisis por Conglomerados , Transmisión de Enfermedad Infecciosa/prevención & control , Salud de la Familia , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Masculino , Enfermedad del Virus de Marburg/mortalidad , Persona de Mediana Edad , Mortalidad , Uganda/epidemiología , Cultivo de VirusRESUMEN
We have developed a digital and multiplexed platform for the rapid detection and telemonitoring of infections caused by Ebola and Marburg filoviruses. The system includes a flow cell assay cartridge that captures specific antibodies with microarrayed recombinant antigens from all six species of filovirus, and a smartphone fluorescent reader for high-performance interpretation of test results. Multiplexed viral proteins, which are expandable to include greater numbers of probes, were incorporated to obtain highest confidence results by cross-correlation, and a custom smartphone application was developed for data analysis, interpretation, and communication. The smartphone reader utilizes an opto-electro-mechanical hardware attachment that snaps at the back of a Motorola smartphone and provides a user interface to manage the operation, acquire test results, and communicate with cloud service. The application controls the hardware attachment to turn on LEDs and digitally record the optically enhanced images. Assay processing time is approximately 20 min for microliter amounts of blood, and test results are digitally processed and displayed within 15 s. Furthermore, a secure cloud service was developed for the telemonitoring of test results generated by the smartphone readers in the field. Assay system results were tested with sera from nonhuman primates that received a live attenuated EBOV vaccine. This integrated system will provide a rapid, reliable, and digital solution to prevent the rapid overwhelming of medical systems and resources during EVD or MVD outbreaks. Further, this disease-monitoring system will be useful in resource-limited countries where there is a need for dispersed laboratory analysis of recent or active infections.
Asunto(s)
Ebolavirus/aislamiento & purificación , Marburgvirus/aislamiento & purificación , Técnicas Microbiológicas/métodos , Técnicas Analíticas Microfluídicas/métodos , Teléfono Inteligente , Animales , Anticuerpos Antivirales/inmunología , Sangre/virología , Ebolavirus/inmunología , Humanos , Inmunoensayo/instrumentación , Inmunoensayo/métodos , Macaca fascicularis , Marburgvirus/inmunología , Ratones , Técnicas Microbiológicas/instrumentación , Técnicas Analíticas Microfluídicas/instrumentación , Nucleoproteínas/inmunología , Pruebas en el Punto de Atención , Prueba de Estudio Conceptual , Análisis por Matrices de Proteínas/instrumentación , Análisis por Matrices de Proteínas/métodos , Conejos , Proteínas del Envoltorio Viral/inmunologíaRESUMEN
Working in accordance with biosafety level four practices is highly complex and time-consuming. Therefore, the respective laboratory protocols should be as uniform as possible, simple to perform and straightforward in readout. Here we describe the successful application of a standardized 24-well plate focus assay protocol for the titration of Zaire ebolavirus (two isolates), Marburg virus (three isolates), Lassa virus (two isolates), Crimean Congo hemorrhagic fever virus (one isolate), and tick-borne encephalitis virus (two isolates). Viral titers are determined based on a simple visual readout. The protocol exhibits high precision, with coefficients of variation for interassay variability ranging between 0.05 and 0.21 and those for intraassay variability between 0.08 and 0.23. All reagents required for the test, including primary and secondary antibodies, are commercially available, facilitating the establishment of the protocol in other laboratories.
Asunto(s)
Contención de Riesgos Biológicos/normas , Carga Viral , Virología/métodos , Virus/aislamiento & purificación , Animales , Chlorocebus aethiops , Ebolavirus/aislamiento & purificación , Virus de la Fiebre Hemorrágica de Crimea-Congo/aislamiento & purificación , Indicadores y Reactivos , Virus Lassa/aislamiento & purificación , Marburgvirus/aislamiento & purificación , Células VeroRESUMEN
Marburg virus haemorrhagic fever (MARV HF) is a dramatic disease that can occur in a traveller returning from an area where the virus is endemic. In this article, we provide an overview of MARV HF as an imported infection with an emphasis on clinical aspects. Although late features such as rash, signs of haemorrhagic diathesis and liver necrosis may point to the diagnosis, the initial clinical picture is non-specific. If in this early phase the patient's epidemiological exposure history is compatible with MARV HF, the patient should be isolated and managed according to viral haemorrhagic fever protocol and RT-PCR should be performed on the patient's blood as soon as possible to rule out MARV HF (or other possible viral haemorrhagic fevers). In severe cases, direct electron microscopy of blood in specialized centres (e.g. Bernhard-Nocht Institute in Hamburg, Germany) may be considered if the result of the RT-PCR is not readily available. Adequate diagnostics and empirical treatment for other acute life-threatening illnesses should not be withheld while test results are awaited, but all management and diagnostics should be weighed against the risks of nosocomial transmission.
Asunto(s)
Enfermedad del Virus de Marburg/diagnóstico , Enfermedad del Virus de Marburg/prevención & control , Marburgvirus/aislamiento & purificación , Enfermedad Relacionada con los Viajes , Animales , Brotes de Enfermedades/prevención & control , Diagnóstico Precoz , Humanos , Control de Infecciones , Enfermedad del Virus de Marburg/patología , Enfermedad del Virus de Marburg/terapia , Marburgvirus/patogenicidadRESUMEN
BACKGROUND/AIMS: Middle East respiratory syndrome coronavirus (MERS-CoV) and Marburg virus (MARV) are among the World Health Organization's top 8 emerging pathogens. Both zoonoses share nonspecific early symptoms, a high lethality rate, and a reduced number of specific treatment options. Therefore, we evaluated extracorporeal virus and glycoprotein (GP) elimination by lectin affinity plasmapheresis (LAP). METHODS: For both MERS-CoV (pseudovirus) as well as MARV (GPs), 4 LAP devices (Mini Hemopurifiers, Aethlon Medical, San Diego, CA, USA) and 4 negative controls were tested. Samples were collected every 30 min and analyzed for reduction in virus infectivity by a flow cytometry-based infectivity assay (MERS-CoV) and in soluble GP content (MARV) by an immunoassay. RESULTS: The experiments show a time-dependent clearance of MERS-CoV of up to 80% within 3 h (pseudovirus). Up to 70% of MARV-soluble GPs were eliminated at the same time. Substantial saturation of the binding resins was detected within the first treatment hour. CONCLUSION: MERS-CoV (pseudovirus) and MARV soluble GPs are eliminated by LAP in vitro. Considering the high lethality and missing established treatment options, LAP should be evaluated in vivo. Especially early initiation, continuous therapy, and timed cartridge exchanges could be of importance.
Asunto(s)
Glicoproteínas/aislamiento & purificación , Marburgvirus/aislamiento & purificación , Coronavirus del Síndrome Respiratorio de Oriente Medio/aislamiento & purificación , Plasmaféresis/métodos , Animales , Estudios de Casos y Controles , Citometría de Flujo , Humanos , Inmunoensayo , Lectinas/metabolismo , Marburgvirus/química , Plasmaféresis/instrumentación , Plasmaféresis/normas , ZoonosisRESUMEN
Ebola viruses (family: Filoviridae) are the cause of Ebola virus disease (EVD), a highly fatal illness characterised by haemorrhagic fever syndrome in both humans and non-human primates (NHPs). West Africa was the epicentre of the 2013-2015 EVD epidemic which caused the death of over 11,000 people, including eight casualties in southern Nigeria. Antibodies to filoviruses have been detected among NHPs in some countries, but there is no documented evidence of exposures to filoviruses among NHPs in Nigeria. From August 2015 to February 2017, a total of 142 serum samples were obtained from individual captive and wild animals, belonging to 11 NHP species, in southern Nigeria, and screened for species-specific antibodies to filoviruses belonging to the species; Zaire ebolavirus [Ebola virus (EBOV)], Sudan ebolavirus [Sudan virus (SUDV)], and Marburg marburgvirus [Ravn virus (RAVV)]-using a modified filovirus species-specific ELISA technique. Of the sera tested, 2.1% (3/142) were positive for antibodies to EBOV. The entire 142 sera were negative for SUDV or RAVV. These findings point to the existence of natural exposures of NHPs in southern Nigeria to EBOV. There is need to discourage, the uncontrolled hunting of NHPs in Nigeria for public health safety.
Asunto(s)
Anticuerpos Antivirales/sangre , Fiebre Hemorrágica Ebola/epidemiología , Primates/inmunología , Animales , Ebolavirus/inmunología , Ebolavirus/aislamiento & purificación , Monitoreo Epidemiológico , Humanos , Marburgvirus/inmunología , Marburgvirus/aislamiento & purificación , Nigeria/epidemiología , Salud Pública/métodosRESUMEN
BACKGROUND: Uganda has reported five (5) Ebola virus disease outbreaks and three (3) Marburg virus disease outbreaks from 2000 to 2016. Peoples' knowledge and attitude towards Ebola and Marburg virus disease impact on control and prevention measures especially during outbreaks. We describe knowledge and attitude towards Ebola and Marburg virus outbreaks in two affected communities in Uganda to inform future outbreak responses and help in the design of health education and communication messages. METHODS: The study was a community survey done in Luweero, Ibanda and Kamwenge districts that have experienced outbreaks of Ebola and Marburg virus diseases. Quantitative data were collected using a structured questionnaire and triangulated with qualitative participatory epidemiology techniques to gain a communities' knowledge and attitude towards Ebola and Marburg virus disease. RESULTS: Out of 740 respondents, 48.5% (359/740) were categorized as being knowledgeable about Ebola and Marburg virus diseases, whereas 60.5% (448/740) were having a positive attitude towards control and prevention of Ebola and Marburg virus diseases. The mean knowledge and attitude percentage scores were 54.3 (SD = 23.5, 95%CI = 52.6-56.0) and 69.9 (SD = 16.9, 95%CI = 68.9-71.1) respectively. People educated beyond primary school were more likely to be knowledgeable about Ebola and Marburg virus disease than those who did not attain any formal education (OR = 3.6, 95%CI = 2.1-6.1). Qualitative data revealed that communities describe Ebola and Marburg virus diseases as very severe diseases with no cure and they believe the diseases spread so fast. Respondents reported fear and stigma suffered by survivors, their families and the broader community due to these diseases. CONCLUSION: Communities in Uganda affected by filovirus outbreaks have moderate knowledge about these diseases and have a positive attitude towards practices to prevent and control Ebola and Marburg viral diseases. The public health sector should enhance this community knowledge gap to empower them more by supplying educational materials for epidemic preparedness in future using appropriate communication channels as proposed by the communities.
Asunto(s)
Brotes de Enfermedades , Métodos Epidemiológicos , Conocimientos, Actitudes y Práctica en Salud , Fiebre Hemorrágica Ebola/epidemiología , Enfermedad del Virus de Marburg/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Niño , Preescolar , Brotes de Enfermedades/prevención & control , Ebolavirus/aislamiento & purificación , Femenino , Fiebre Hemorrágica Ebola/prevención & control , Fiebre Hemorrágica Ebola/psicología , Fiebre Hemorrágica Ebola/virología , Humanos , Entrevistas como Asunto , Masculino , Enfermedad del Virus de Marburg/prevención & control , Enfermedad del Virus de Marburg/psicología , Enfermedad del Virus de Marburg/virología , Marburgvirus/aislamiento & purificación , Persona de Mediana Edad , Salud Pública/métodos , Salud Pública/estadística & datos numéricos , Estigma Social , Uganda/epidemiología , Adulto JovenRESUMEN
The first reported filovirus outbreak occurred in August 1967, when laboratory workers in Marburg and Frankfurt, Germany, and Belgrade, Yugoslavia (now Serbia) became infected with an unknown highly pathogenic agent. The disease was characterized by high fever, malaise, rash, hemorrhagic and tetanic manifestations, and high lethality, amounting to 25%. The disease was introduced to Europe by grivets (Chlorocebus aethiops), which were used for biomedical research and vaccine production. The causative agent, Marburg virus, was isolated and identified by scientists of the University of Marburg, Germany in cooperation with specialists for viral electron microscopy at the Bernhard Nocht Institute in Hamburg, Germany. In this chapter, Dr. Slenczka, who was involved in the first isolation of Marburg virus in 1967, describes the desperate hunt of the causative agent of this first filovirus disease outbreak in the center of Europe, its successful isolation, the likely route of transmission from a monkey trading station to vaccine production facilities in Germany and Yugoslavia, and the consequences of this outbreak, including a shortage in the production of poliomyelitis vaccine In addition, this chapter provides insight into some of the peculiarities of filovirus infection, such as sexual virus transmission several months after recovery and the role of Ca2+-loss in Marburg virus pathogenesis, which were already observed during this first well-documented Marburg virus disease outbreak.
Asunto(s)
Investigación Biomédica/historia , Brotes de Enfermedades/historia , Filoviridae , Fiebre Hemorrágica Ebola/historia , Enfermedad del Virus de Marburg/historia , Animales , Chlorocebus aethiops/virología , Brotes de Enfermedades/estadística & datos numéricos , Europa (Continente)/epidemiología , Filoviridae/aislamiento & purificación , Fiebre Hemorrágica Ebola/epidemiología , Fiebre Hemorrágica Ebola/transmisión , Historia del Siglo XX , Humanos , Enfermedad del Virus de Marburg/epidemiología , Enfermedad del Virus de Marburg/transmisión , Marburgvirus/aislamiento & purificaciónRESUMEN
Marburg virus (MARV) has caused outbreaks of filoviral hemorrhagic fever since its discovery in 1967. The largest and deadliest outbreak occurred in Angola in 2005, with 252 cases and 227 deaths. In 2014, we developed a mouse-adapted MARV, Angola variant through serial passaging in mice. The mouse-adapted MARV exhibits many of the hallmarks of MARV disease in humans. By applying deep-sequencing to every passage of the virus, we are able to study virus evolution in this host with surprising precision. We show that two regions go through substantial changes: the intergenic region between NP and VP35, as well as the first 100 amino acids of the VP40 protein. Our results also reveal that there were profound changes during the production of the final virus stock in cell culture. Overall, our results show that a handful of regions carry most of the mutations acquired during the adaptation of the virus to a new host and that many mutations become fixed very early during the adaptation process.
Asunto(s)
Adaptación Biológica/genética , Genoma Viral , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Enfermedad del Virus de Marburg/patología , Enfermedad del Virus de Marburg/virología , Marburgvirus/genética , Proteínas Virales/genética , Animales , Células Cultivadas , Enfermedad del Virus de Marburg/genética , Marburgvirus/crecimiento & desarrollo , Marburgvirus/aislamiento & purificación , Ratones , ARN Viral/genética , Pase Seriado , Carga ViralRESUMEN
In September 2014, a single fatal case of Marburg virus was identified in a healthcare worker in Kampala, Uganda. The source of infection was not identified, and no secondary cases were identified. We describe the rapid identification, laboratory diagnosis, and case investigation of the third Marburg virus outbreak in Uganda.